Pharmalucence gets FDA approval for generic Cardiolite

07/20/2009 | Mass High Tech (Boston)

The FDA gave radiopharmaceutical supplier Pharmalucence the green light to develop and market a generic version of Lantheus Medical Imaging's Cardiolite, a diagnostic imaging agent for coronary artery disease. Pharmalucence's product, the Kit for the Preparation of Technetium Tc-99m Sestamibi Injection, is used for identifying myocardial ischemia and infarction.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA